Cardiological society of India position statement on COVID-19 and heart failure
S Harikrishnan, P.P. Mohanan, Vijay Chopra, Roy Ambuj, G. Sanjay, Manish Bansal, Rajarshi Chakraborty, Sharad Chandra, S S Chattarjee, H K Chopra, Cibu Mathew, Pradip Kumar Deb, Ankita Goyal, Kalyan Goswami, Rakesh Gupta, Santanu Guha, Varun Gupta, P.K. Hasija, Harsh Wardhan, A. Jabir, P.B. Jayagopal, Dhiman Kahali, V K Katyal, P.G. Kerkar, Narendra N. Khanna, Biswajit Majumder, Manoranjan Mandal, Chandra Bhan Meena, Nitish Naik, VarunShankar Narain, Lekha Pathak, Saumitra Ray, Debabrata Roy, Satyanarayan Routray, Dipak Kumar Sarma, Saseendar Shanmugasundaram, B.P. Singh, Sanjay Tyagi, K Venugopal, GS Wander, Rakesh Kumar Yadav, Mrinal Kanti Das
Abstract
Abstract The COVID 19 global pandemic has engulfed humanity with a huge impact on health systems across the world. Many patients develop myocardial injury which can lead to significant cardiovascular complications including HF. This will require aggressive management strategies which are evolving. Guideline directed drug therapy including ACEI/ARB/ARNI is to be continued in patients with pre-existing HF. Long-term cardiovascular effects of COVID-19 are yet to be ascertained. Protection of health care personnel from contracting the disease should be given high priority.